Evolution of neutralizing antibody response against HIV type 1 virions and pseudovirions in multicenter AIDS cohort study participants

AIDS Research and Human Retroviruses

Volumn 14, Issue 11, 1998, Pages 939-949

  Quinnan Jr , Gerald V ^a   Zhang, Peng Fei ^a   Fu, Da Wei ^a   Dong, Ming ^a,b   Margolick, Joseph B ^c  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

^b National Vaccine and Serum Institute   (China)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

ANTIBODY TITER; ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; VIRION; VIRUS ENVELOPE; VIRUS GENE; VIRUS NEUTRALIZATION;

EID: 0032551540     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1998.14.939     Document Type: Article

References (65)

1. Luciw PA: In: Fields Virology (Fields BN, Knipe DM, and Howley PM, eds.), 3rd Ed. Lippincott-Raven, Philadelphia, 1996, pp. 1881-1952.
2. Thali M, Furman C, Ho DD, Robinson J, Tilley S, Pinter A, and Sodroski J: Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol 1992;66:5635-5641.
3. Zwart G, Langedijk H, Van der Hoek L, de Jong JJ, Wolfs TF, Ramautarsing C, Bakker M, De Ronde A, and Goudsmit J: Immunodominance and antigenic variation of the principal neutralization domain of HIV-1. Virology 1991;181:481-489.
4. Moore JP, Sattentau QJ, Yoshiyama H, Thali M, Charles M, Sullivan N, Poon S-W, Fung MS, Traincard F, Pinkus M, Robey G, Robinson JE, Ho DD, and Sodroski J: Probing the structure of the V2 domain of human immunodeficiency virus type 1 surface glycoprotein gp120 with a panel of eight monoclonal antibodies: Human immune response to the V1 and V2 domains. J Virol 1993;67:6136-6151.
5. Trkola A, Punscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivassan K, Sodroski J, Moore JP, and Katinger H: Human monoclonal antibody 2G12 defines a distinctive neutralization epitope of human immunodeficiency virus type 1. J Virol 1996; 70:1100-1108.
6. Muster T, Stein F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H: A conserved neutralization epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993;67: 6642-6647.
7. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, and Sodroski J: Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4. J Virol 1993;67:3978-3988.
8. Cotropia J, Ugen KE, Kliks S, Broliden K, Broliden PA, Hoxie JA, Srikantan V, Williams WV, and Weiner DB: A human monoclonal antibody to HIV-1 gp41 with neutralizing activity against diverse laboratory isolates. J Acquir Immune Defic Syndr Hum Retrovirol 1996;12:221-232.
9. Sabri F, Chiodi F, and Fenyö EM: Lack of correlation between V3 amino acid sequence and syncytium-inducing capacity of some HIV type 1 isolates. AIDS Res Hum Retroviruses 1996:12: 855-858.
10. Thali M, Charles M, Furman C, Cavacini L, Posner M, Robinson J, and Sodroski J: Resistance to neutralization by broadly reactive antibodies to the human immunodeficiency virus type 1 gp120 glycoprotein conferred by a gp41 amino acid change. J Virol 1994;68: 674-680.
11. Back NKT, Smit L, Schutten M, Nara PL, Tersmette M, and Goudsmit J: Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol 1993;67:6897-6902.
12. Myers G, Berzofsky JA, Korber B, Smith RF, and Pavlakis GN: Human Retroviruses and AIDS 1992. Los Alamos National Laboratory, Los Alamos, New Mexico, 1993.
13. Willey RL, Rutledge RA, Dias S, Folks T, Theodore T, Buckler CE, and Martin MA: Identification of conserved and divergent domains within the envelope gene of the acquired immunodeficiency syndrome retrovirus. Proc Natl Acad Sci USA 1986;83:5038-5042.
14. McKeating JA, Schotton C, Cordell J, Graham S, Balfe P, Sullivan N, Charles M, Page M, Bolmstedt A, Olofsson S, Kayman SC, Wu Z, Pinter A, Dean C, Sodroski J, and Weiss RA: Characterization of neutralizing monoclonal antibodies to linear and conformation-dependent epitopes within the first and second variable domains of human immunodeficiency virus type 1 gp120. J Virol 1993;67:4932-4944.
15. O'Brien WA, Chen ISY, Ho DD, and Daar ES: Mapping genetic determinants for human immunodeficiency virus type 1 resistance to soluble CD4. J Virol 1992;66:3125-3130.
16. McKeating JA, Giw J, Goudsmit J, Pearl LH, Mulder C, and Weiss RA: Characterization of HIV-1 neutralization escape mutants. AIDS 1989;3:777-784.
17. Ho DD, Fung MSC, Cao Y, Li XL, Sun C, and Chang TW: Another discontinuous epitope on glycoprotein gp120 that is important in human immunodeficiency virus type 1 neutralization is identified by a monoclonal antibody. Proc Natl Acad Sci USA 1991;88:8949-8952.
18. McKnight A and Clapham PR: Immune escape and tropism of HIV. Trends Microbiol 1995;3:356-361.
19. Arendrup M, Sonnerborg A, Svennerholm B, Akerblom L, Nielsen C, Clausen H, Olofsson S, Nielsen JO, and Hansen JE: Neutralizing antibody response during human immunodeficiency virus type 1 infection: Type and group specificity and viral escape. J Gen Virol 1993;74:855-863.
20. McKnight A, Clapham PR, Goudsmit J, Cheingsong-Popov R, Weber JN, and Weiss RA: Development of HIV-1 group-specific neutralizing antibodies after seroconversion. AIDS 1992;6:799-802.
21. Langedijk JP, Zwart G, Goudsmit J, and Meloen RH: Fine specificity of antibody recognition may predict amino acid substitution in the third variable region of gp120 during HIV type 1 infection. AIDS Res Hum Retroviruses 1995;11:1153-1162.
22. Wahlberg J, Albert J, Lundeberg J, Von Gegerfelt A, Broliden K, Utter G, Fenyö EM, and Uhlen M: Analysis of the V3 loop in neutralization-resistant human immunodeficiency virus type 1 variants by direct solid-phase DNA sequencing. AIDS Res Hum Retroviruses 1991;7:983-990.
23. Nara PL, Smit L, Dunlop N, Hatch W, Merges M, Waters D, Kelliher J, Gallo RC, Fischinger PJ, and Goudsmit J: Emergence of viruses resistant to neutralization by V3 specific antibodies in experimental human immunodeficiency virus type 1 IIIB infection of chimpanzees. J Virol 1990;64:3779-3791.
24. Back NKT, Smit L, Schutten M, Nara PL, Tersmette M, and Goudsmit J: Mutations in human immunodeficiency virus type 1 gp41 affect sensitivity to neutralization by gp120 antibodies. J Virol 1993;67:6897-6902.
25. Korber B, Wolinsky S, Haynes B, Kunstman K, Levy R, Furtado M, Otto P, and Myers G: HIV-1 intrapatient sequence diversity in the immunogenic V3 region. AIDS Res Hum Retroviruses 1992;8:1461-1465.
26. Robert-Guroff M, Reitz MS, Robey WG, and Gallo RC: In vitro generation of an HTLV-III variant by neutralizing antibody. J Immunol 1986;137:3306-3309.
27. Reitz MS, Wilson C, Naugle C, Gallo RC, and Robert-Guroff M: Generation of a neutralization resistant variant of HIV-1 is due to selection for a point mutation in the envelope gene. Cell 1988;54:57-63.
28. Watkins BA, Buge S, Aldrich K, Davis AE, Robinson J, Reitz MS Jr, and Robert-Guroff M: Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites. J Virol 1996;70:8431-8437.
29. Purcell DF and Martin MA: Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity. J Virol 1993;67:6365-6378.
30. Blumberg BM, Epstein LG, Saito Y, Chen D, Sharer LR, and Anand R: Human immunodeficiency virus type 1 nef quasispecies in pathological tissue. J Virol 1992;66:5256-5264.
31. Englund G, Hoggan M, Theodore T, and Martin MA: A novel HIV-1 isolate containing alterations affecting the NF-κ element. Virology 1991;181:150-157.
32. Gendelman HE, Orenstein JM, Martin MA, Ferma C, Mitra R, Phipps T, Wahl LA, Lane HC, Fauci AS, and Burke DS: Efficient isolation and propagation of human immunodeficiency virus on recombinant colony-stimulating factor 1-treated monocytes. J Exp Med 1998;167:1428-1441.
33. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59: 284-291.
34. Englund G, Theodore TS, Freed EO, Engleman A, and Martin MA: Integration is required for productive infection of monocyte-derived macrophages by human immunodeficiency virus type 1. J Virol 1995;69:3216-3219.
35. Levy JA, Cheng-Mayer C, Dina D, and Luciw PA: AIDS retrovirus (ARV-2) clone replicates in transfected human and animal fibroblasts. Science 1986;232:998-1001.
36. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major coreceptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
37. He J, Choe S, Walker R, Di Marzio P, Morgan DO, and Landau NR: Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 1995;69:6705-6711.
38. Page KA, Landau NR, and Littman DR: Construction and use of a human immunodeficiency virus vector for analysis of virus infectivity. J Virol 1990;64:5270-5276.
39. Stuve LL, Brown-Shimer S, Pachl C, Naharian R, Diaz D, and Burke RL: Structure and expression of the herpes simplex virus type 2 glycoprotein gB gene. J Virol 1987;61:326-335.
40. Mann DL, O'Brien SJ, Gilbert DA, Reid Y, Popovic M, Read-Connole E, Gallo RC, and Gazdar AF: Origin of the HIV-susceptible human CD4+ cell line H9. AIDS Res Hum Retroviruses 1989; 5:253-255.
41. Daniel MD, Li Y, Naidu YM, Durda PJ, Schmidt DK, Troup CD, Silva DP, MacKey JJ, Kestler HW III, Sehgal PK, et al.: Simian immunodeficiency virus from African green monkeys. J Virol 1988;62:4123-4128.
42. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NL: Identification of a major co-receptor for primary isolates of HIV. Nature (London) 1996;381:661-666.
43. Landau NR and Littman DR: Packaging system for rapid production of murine leukemia virus vectors with variable tropism. J Virol 1992;66:5110-5113.
44. Lusso P, Cocchi F, Balotta C, Markham PD, Louie A, Farci P, Pal R, Gallo RC, and Reitz MS Jr: Growth of macrophage-tropic and primary human immunodeficiency virus type 1 (HIV-1) isolates in a unique CD4+ T-cell clone (PM1): Failure to downregulate CD4 and to interfere with cell-line-tropic HIV-1. J Virol 1995;69: 3712-3720.
45. Liou HC, Sha WC, Scott ML, and Baltimore D: Sequential induction of NF-kappa B/Rel family proteins during B-cell terminal differentiation. Mol Cell Biol 1994;14:5349-5359.
46. Theodore TS, Englund G, Buckler-White A, Buckler CE, Martin MA, and Peden KW: Construction and characterization of a stable full-length macrophage-tropic HIV type molecular clone that directs the production of high liters of progeny virions. AIDS Res Hum Retroviruses 1996;12:191-194.
47. Mascola J, Louwagie J, McCutchan FE, Fischer CL, Hegerich PA, Wagner KF, Fowler AK, McNeil JG, and Burke DS: Two antigenically distinct subtypes of human immunodeficiency virus type 1: Viral genotype predicts neutralization serotype. J Infect Dis 1994;169:48-54.
48. Detels R, Liu Z, Hennessey K, Kan J, Visscher BR, Taylor JM, Hoover DR, Rinaldo CR Jr, Phair JP, Saah AJ, et al.: Resistance to HIV-1 infection. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr 1994;7:1263-1269.
49. Vujcic L, Katzenstein D, Martin M, and Quinnan GV: International collaborative study to compare assays for antibodies that neutralize human immunodeficiency virus. AIDS Res Hum Retroviruses 1990;6:847-853.
50. Vujcic LK, Shepp DH, Klutch M, Wells MA, Hendry RM, Wittek AE, Krilov L, and Quinnan GV: Use of a sensitive neutralization assay to measure the prevalence of antibodies to the human immunodeficiency virus. J Infect Dis 1988;157:1047-1050.
51. Vujcic LK and Quinnan GV Jr: Preparation and characterization of human HIV type 1 neutralizing reference sera. AIDS Res Hum Retroviruses 1995;11:783-787.
52. Chen Z, Zhou P, Ho DD, Landau NR, and Marx PA: Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol 1997;71:2705-2714.
53. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, and Landau NR: Identification of a major co-receptor for primary isolates of HIV-1. Nature (London) 1996;381:661-666.
54. Sambrook J, Fritsch EF, and Maniatis T (eds.): In vitro amplification of DNA by the polymerase chain reaction: Amplification of DNA generated by reverse transcription of mRNA. In: Molecular Cloning: A Laboratory Manual, 2nd Ed., Chapter 15: Site Directed Mutagenesis of Cloned DNA. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1987, pp. 1420-1421.
55. Cariello NF, Swenberg JA, and Skopek TR: Fidelity of Thermococcus litoralis DNA polymerase (Vent) in PCR determined by denaturing gradient gel electrophoresis. Nucleic Acids Res 1991;19:4193-4198.
56. Barnes WM: The fidelity of Taq polymerase catalyzing PCR is improved by an N-terminal deletion. Gene 1992;112:29-35.
57. Sutton RE and Littman DR: Broad host range of human T-cell leukemia virus type 1 demonstrated with an improved pseudotyping system. J Virol 1996;70:7322-7326.
58. Lennette EH: General principles underlying laboratory diagnosis of viral and rikettsial infections. In: Diagnostic Procedures of Viral and Rickettsial Disease (Lennette EH and Schmidt MJ, eds.). American Public Health Association, New York, 1964, p. 45.
59. Fitzgerald EA, Gallagher M, Hunter WS, and Seligmann EB Jr: Use of the antibody assay in immunized mice for the determination of rabies vaccine potency. Dev Biol Stand 1978;40:183-186.
60. Klenerman P and Zinkernagel RM: What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev 1997;159:5-16.
61. Quinnan G, Manischewitz J, and Ennis FA: Role of cytotoxic T lymphocytes in murine cytomegalovirus infection. J Gen Virol 1980;47:503-508.
62. Quinnan GV, Kirmani N, Rook AH, Manischewitz JF, Jackson L, Moreschi G, Santos G, Saral R, and Burns W: Cytotoxic T cells in cytomegalovirus infection HLA-restricted T-lymphocyte and non-T lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Engl J Med 1982;307:7-13.
63. Nyambi PN, Lewi P, Peeters M, Janssens W, Heyndricks L, Fransen K, Andries K, Vanden Haesevelde M, Heeney J, Piot P, and van der Groen GJ: Study of the dynamics of neutralization escape mutants in a chimpanzee naturally infected with the simian immunodeficiency virus SIVcpz-ant. Virology 1997;71:2320-2330.
64. Delwart EL, Pan H, Sheppard HW, Wolpert D, Neumann AU, Korber B, and Mullins JI: Slower evolution of human immunodeficiency virus type 1 quasispecies during progression to AIDS. J Virol 1997;71:7498-7508.
65. Martin N, Koup R, Kaslow R, Coffin J, and Ammann A: Workshop on perinatally acquired human immunodeficiency virus infection in long-term surviving children: A collaborative study of factors contributing to slow disease progression. The Long-Term Survivor Project. AIDS Res Hum Retroviruses 1996;12: 1565-1570.